Syneos Health and fitness Announces Secondary Providing of Typical Inventory Nasdaq:SYNH

MORRISVILLE, N.C., March 01, 2021 (World NEWSWIRE) — Syneos Well being, Inc. (Nasdaq: SYNH) (the

MORRISVILLE, N.C., March 01, 2021 (World NEWSWIRE) — Syneos Well being, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only totally built-in biopharmaceutical answers organization combining a CRO (Contract Analysis Firm) and a CCO (Deal Industrial Firm), right now introduced it commenced an underwritten secondary presenting by affiliate marketers of Thomas H. Lee Partners, L.P. and Arrival Worldwide Company (the “Selling Stockholders”) of an mixture of 7,000,000 shares of the Company’s common inventory (the “Offering”) pursuant to the Company’s shelf registration assertion submitted with the Securities and Exchange Fee (“SEC”). The Promoting Stockholders intend to grant the underwriter a 30-day selection to invest in up to 1,050,000 supplemental shares of common inventory. Syneos Health is not offering any shares and will not acquire any proceeds from the sale of the shares by the Offering Stockholders in the Providing.

In addition, Syneos Wellbeing entered into an arrangement with the Providing Stockholders to repurchase an aggregate of 600,000 shares of prevalent inventory from this sort of Selling Stockholders in a personal transaction, concurrently with the closing of the Providing, at the cost at which the shares of prevalent stock are offered to the general public in the Supplying, significantly less underwriting discounts and commissions. The closing of the share repurchase is contingent on, and predicted to occur at the same time with, the closing of the Offering, issue to the fulfillment of other customary ailments. The closing of the Supplying is not contingent on the closing of the share repurchase.

Goldman Sachs & Co. LLC is acting as the sole underwriter of the Offering.

An computerized shelf registration statement (such as a prospectus) relating to the Offering was submitted with the SEC on November 27, 2018 and grew to become productive upon submitting. Ahead of you devote, you should really go through the registration statement, prospectus and other paperwork Syneos Well being has manufactured obtainable with the SEC for details about Syneos Well being and the Offering. You may well obtain these documents totally free of charge by checking out EDGAR on the SEC web site at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus complement, when readily available, may possibly be obtained from:

Goldman Sachs & Co. LLC
Awareness: Prospectus Division
200 West Avenue
New York, NY 10282
Phone: +1 866 471 2526
Facsimile: +1 212 902 9316
Electronic mail: [email protected] mail.gs.com.

This push release shall not represent an present to market or the solicitation of an give to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an give, solicitation or sale would be unlawful prior to registration or qualification underneath the securities laws of any these types of condition or other jurisdiction.

Ahead-On the lookout Statements

Besides for historic information and facts, all of the statements, anticipations, and assumptions contained in this press launch are ahead-looking statements as that time period is defined in the Private Securities Litigation Reform Act of 1995. Actual outcomes could differ materially from people express or implicit in the forward-seeking statements. Vital factors that could induce true outcomes to differ materially involve, but are not limited to: reliance on crucial personnel principal investigators and individuals standard and global economic, political, and other risks, including forex and inventory sector fluctuations and the uncertain economic ecosystem any failure to comprehend the expected advantages of the acquisitions of SHCR Holdings Corporation, or Synteract, and Illingworth Exploration Group challenges associated to the COVID-19 pandemic the Company’s capability to sufficiently value its contracts and not overrun cost estimates any adverse results from the Company’s client or therapeutic location focus the Company’s skill to retain or produce new business awards the Company’s potential to increase its current market share, increase its enterprise, and execute its progress methods the Company’s backlog not staying indicative of long term revenues and its capability to notice the predicted long run revenue reflected in its backlog fluctuations in the Company’s operating benefits and successful revenue tax charge risks associated to the Company’s details systems and cybersecurity changes and fees of compliance with polices related to knowledge privateness dangers connected to the United Kingdom’s withdrawal from the European Union dangers associated to the Company’s transfer pricing policies failure to conduct services in accordance with contractual prerequisites, regulatory prerequisites and moral issues dangers relating to litigation and authorities investigations threats affiliated with the Company’s early stage clinical services insurance policies danger challenges of liability ensuing from harm to sufferers achievements of investments in the Company’s customers’ business enterprise or drugs overseas forex trade amount fluctuations hazards connected with obtained companies, which includes the means to integrate acquired functions, products and solutions, and systems in our business threats similar to the Company’s money tax cost and tax reform dangers relating to the Company’s intellectual house threats affiliated with the Company’s acquisition strategy failure to recognize the entire benefit of goodwill and intangible assets restructuring danger potential violations of anti-corruption and anti-bribery regulations dangers connected to the Company’s dependence on third parties downgrades of the Company’s credit ratings competitors in the biopharmaceutical providers business modifications in outsourcing tendencies regulatory challenges developments in the Company’s customers’ companies the Company’s ability to maintain pace with swift technological change challenges connected to the Company’s indebtedness fluctuations in the Company’s financial effects and inventory selling price and other chance factors established forth in the Company’s Once-a-year Report on Sort 10-K for the fiscal calendar year ended December 31, 2020 and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The Company assumes no obligation and does not intend to update these ahead-seeking statements, other than as necessary by law.

About Syneos Health and fitness

Syneos Well being® (Nasdaq:SYNH) is the only fully built-in biopharmaceutical methods firm. The Business, which includes a Deal Research Corporation (CRO) and Deal Business Corporation (CCO), is purpose-built to accelerate consumer performance to deal with present day market place realities. We provide collectively roughly 25,000 clinical and professional minds with the capacity to help buyers in far more than 110 countries. Together we share insights, use the latest technologies and implement state-of-the-art business techniques to pace our customers’ shipping and delivery of crucial therapies to clients.